Moderna, Inc.

Moderna shares double as cancer vaccine data rekindles investor hopes

Moderna shares surged over 100% following positive late-stage data showing its mRNA cancer therapy with Merck reduced skin cancer recurrence. Analysts project $1.4 billion in sales potential by 2032,